...
首页> 外文期刊>Journal of Scientific Research >Formulation and Evaluation of Fixed Dose Combination Suppositories Containing Stavudine, Lamivudine and Nevirapine for Pediatric Applications
【24h】

Formulation and Evaluation of Fixed Dose Combination Suppositories Containing Stavudine, Lamivudine and Nevirapine for Pediatric Applications

机译:小儿应用含司他夫定,拉米夫定和奈韦拉平固定剂量组合栓剂的研制与评价

获取原文
           

摘要

Suppositories are the convenient way of administering drugs in infants. In view of the lack of suitable pediatric antiretroviral formulations in the market, suppositories containing fixed dose combination (FDC) of stavudine, lamivudine and nevirapine (SLN) were developed to allow administration of the correct weight-related dose in pediatric HIV patients as recommended by WHO. Suppositories containing 10 mg of stavudine, 40 mg of lamivudine and 70 mg of nevirapine were prepared by the fusion method using Witepsol H15 semi-synthetic suppository base. All the prepared suppositories were evaluated for various physical parameters like weight variation, melting point, drug content and hardness. The rate and extent of drug release was evaluated using USP apparatus I and samples were analyzed by a validated UV-multicomponent method. The use of surfactants significantly increased the drug release from formulations manufactured with Witepsol H 15 fatty base. The development of pediatric fixed-dose combination formulations represent a new era and mark an important milestone for children living with HIV/AIDS.
机译:栓剂是在婴儿中给药的简便方法。鉴于市场上缺乏合适的儿科抗逆转录病毒制剂,研制了含有司他夫定,拉米夫定和奈韦拉平(SLN)固定剂量组合(FDC)的栓剂,以允许按照艾滋病毒/艾滋病患者的建议以正确的体重相关剂量给药WHO。使用Witepsol H15半合成栓剂基质,通过融合法制备了含有10 mg司他夫定,40 mg拉米夫定和70 mg奈韦拉平的栓剂。评价所有制备的栓剂的各种物理参数,例如重量变化,熔点,药物含量和硬度。使用USP设备I评估药物释放的速率和程度,并通过经过验证的UV多组分方法分析样品。表面活性剂的使用显着增加了用Witepsol H 15脂肪碱生产的制剂的药物释放。儿科固定剂量组合制剂的开发代表了一个新时代,并标志着艾滋病毒/艾滋病儿童的重要里程碑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号